The application of microarray technology to the analysis of the cancer genome

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

The identification genetic events that are involved in the development of human cancer has been facilitated through the development and application of a diverse series of high resolution, high throughput microarray platforms. Essentially there are two types of array; those that carry PCR products from cloned nucleic acids (e.g. cDNA, BACs, cosmids) and those that use oligonucleotides. Each has advantages and disadvantages but it is now possible to survey genome wide DNA copy number abnormalities and expression levels to allow correlations between losses, gains and amplifications in tumor cells with genes that are over-and under-expressed in the same samples. The gene expression arrays that provide estimates of mRNA levels in tumors have given rise to exonspecific arrays that can identify both gene expression levels, alternative splicing events and mRNA processing alterations. Oligonucleotide arrays are also being used to Interrogate single nucleotide polymorphisms (SNPs) throughout the genome for linkage and association studies and these have been adapted to quantify copy number abnormalities and loss of heterozygosity events. To identify as yet unknown transcripts tiling arrays across the genome have been developed which can also identify DNA methylation changes and be used to identify DNA-protein interactions using Chlp on Chip protocols. Ultimately DNA sequencing arrays will allow resequencing of chromosome regions and whole genomes. With all of these capabilities becoming routine in genomics laboratories, the idea of a systematic characterization of the sum genetic events that give rise to a cancer cell is rapidly becoming a reality.

Original languageEnglish (US)
Pages (from-to)103-120
Number of pages18
JournalCurrent Molecular Medicine
Volume7
Issue number1
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Microarrays
Genes
Genome
Technology
Oligonucleotide Array Sequence Analysis
Neoplasms
Gene expression
Oligonucleotides
Tumors
DNA
Gene Expression
Cosmids
Messenger RNA
Cells
Loss of Heterozygosity
Alternative Splicing
Human Development
DNA Methylation
Genomics
DNA Sequence Analysis

Keywords

  • Cloned nucleic acids
  • Comparative genomic hybridization
  • CpG dinucleotides
  • Loss of heterozygosity (LOH)
  • Single nucleotide polymorphisms (SNPs)
  • Tiling array

ASJC Scopus subject areas

  • Biochemistry

Cite this

The application of microarray technology to the analysis of the cancer genome. / Cowell, John Kenneth; Hawthorn, Lesleyann.

In: Current Molecular Medicine, Vol. 7, No. 1, 01.02.2007, p. 103-120.

Research output: Contribution to journalReview article

@article{4ce87c9b9be74d4e8dee64c105db8f6e,
title = "The application of microarray technology to the analysis of the cancer genome",
abstract = "The identification genetic events that are involved in the development of human cancer has been facilitated through the development and application of a diverse series of high resolution, high throughput microarray platforms. Essentially there are two types of array; those that carry PCR products from cloned nucleic acids (e.g. cDNA, BACs, cosmids) and those that use oligonucleotides. Each has advantages and disadvantages but it is now possible to survey genome wide DNA copy number abnormalities and expression levels to allow correlations between losses, gains and amplifications in tumor cells with genes that are over-and under-expressed in the same samples. The gene expression arrays that provide estimates of mRNA levels in tumors have given rise to exonspecific arrays that can identify both gene expression levels, alternative splicing events and mRNA processing alterations. Oligonucleotide arrays are also being used to Interrogate single nucleotide polymorphisms (SNPs) throughout the genome for linkage and association studies and these have been adapted to quantify copy number abnormalities and loss of heterozygosity events. To identify as yet unknown transcripts tiling arrays across the genome have been developed which can also identify DNA methylation changes and be used to identify DNA-protein interactions using Chlp on Chip protocols. Ultimately DNA sequencing arrays will allow resequencing of chromosome regions and whole genomes. With all of these capabilities becoming routine in genomics laboratories, the idea of a systematic characterization of the sum genetic events that give rise to a cancer cell is rapidly becoming a reality.",
keywords = "Cloned nucleic acids, Comparative genomic hybridization, CpG dinucleotides, Loss of heterozygosity (LOH), Single nucleotide polymorphisms (SNPs), Tiling array",
author = "Cowell, {John Kenneth} and Lesleyann Hawthorn",
year = "2007",
month = "2",
day = "1",
doi = "10.2174/156652407779940387",
language = "English (US)",
volume = "7",
pages = "103--120",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - The application of microarray technology to the analysis of the cancer genome

AU - Cowell, John Kenneth

AU - Hawthorn, Lesleyann

PY - 2007/2/1

Y1 - 2007/2/1

N2 - The identification genetic events that are involved in the development of human cancer has been facilitated through the development and application of a diverse series of high resolution, high throughput microarray platforms. Essentially there are two types of array; those that carry PCR products from cloned nucleic acids (e.g. cDNA, BACs, cosmids) and those that use oligonucleotides. Each has advantages and disadvantages but it is now possible to survey genome wide DNA copy number abnormalities and expression levels to allow correlations between losses, gains and amplifications in tumor cells with genes that are over-and under-expressed in the same samples. The gene expression arrays that provide estimates of mRNA levels in tumors have given rise to exonspecific arrays that can identify both gene expression levels, alternative splicing events and mRNA processing alterations. Oligonucleotide arrays are also being used to Interrogate single nucleotide polymorphisms (SNPs) throughout the genome for linkage and association studies and these have been adapted to quantify copy number abnormalities and loss of heterozygosity events. To identify as yet unknown transcripts tiling arrays across the genome have been developed which can also identify DNA methylation changes and be used to identify DNA-protein interactions using Chlp on Chip protocols. Ultimately DNA sequencing arrays will allow resequencing of chromosome regions and whole genomes. With all of these capabilities becoming routine in genomics laboratories, the idea of a systematic characterization of the sum genetic events that give rise to a cancer cell is rapidly becoming a reality.

AB - The identification genetic events that are involved in the development of human cancer has been facilitated through the development and application of a diverse series of high resolution, high throughput microarray platforms. Essentially there are two types of array; those that carry PCR products from cloned nucleic acids (e.g. cDNA, BACs, cosmids) and those that use oligonucleotides. Each has advantages and disadvantages but it is now possible to survey genome wide DNA copy number abnormalities and expression levels to allow correlations between losses, gains and amplifications in tumor cells with genes that are over-and under-expressed in the same samples. The gene expression arrays that provide estimates of mRNA levels in tumors have given rise to exonspecific arrays that can identify both gene expression levels, alternative splicing events and mRNA processing alterations. Oligonucleotide arrays are also being used to Interrogate single nucleotide polymorphisms (SNPs) throughout the genome for linkage and association studies and these have been adapted to quantify copy number abnormalities and loss of heterozygosity events. To identify as yet unknown transcripts tiling arrays across the genome have been developed which can also identify DNA methylation changes and be used to identify DNA-protein interactions using Chlp on Chip protocols. Ultimately DNA sequencing arrays will allow resequencing of chromosome regions and whole genomes. With all of these capabilities becoming routine in genomics laboratories, the idea of a systematic characterization of the sum genetic events that give rise to a cancer cell is rapidly becoming a reality.

KW - Cloned nucleic acids

KW - Comparative genomic hybridization

KW - CpG dinucleotides

KW - Loss of heterozygosity (LOH)

KW - Single nucleotide polymorphisms (SNPs)

KW - Tiling array

UR - http://www.scopus.com/inward/record.url?scp=33847261476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847261476&partnerID=8YFLogxK

U2 - 10.2174/156652407779940387

DO - 10.2174/156652407779940387

M3 - Review article

VL - 7

SP - 103

EP - 120

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 1

ER -